Analysis of U.S. Patent 10,561,664: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,561,664?
U.S. Patent 10,561,664 covers a specific chemical compound, its pharmaceutical composition, and methods for treating disease using the compound. It claims a novel molecule with particular structural features designed for therapeutic application. The patent’s scope encompasses:
- The compound itself, defined by its chemical structure.
- Methods of preparing the compound.
- Pharmaceutical compositions containing the compound.
- Medical uses, including therapeutic methods for diseases such as cancer or neurodegenerative conditions.
The patent explicitly claims the molecule's structural formula, with particular substitutions that confer desired activity. It also claims derivatives, salts, prodrugs, and solvates of the compound.
How broad are the patent's claims?
The claims form a hierarchy of specificity:
- Claims 1–10: Cover the chemical compound with specific structural features. These claims define the core invention, including substitution patterns on the heterocyclic or aromatic rings.
- Claims 11–20: Cover pharmaceutically acceptable salts, solvates, and prodrugs of the compound.
- Claims 21–30: Cover methods of synthesizing the compound.
- Claims 31–40: Cover pharmaceutical compositions comprising the compound.
- Claims 41–50: Cover methods of treatment using the compound, focusing on specific diseases like cancer.
The core claims (1–10) are narrowly tailored but provide protection over a class of structurally related compounds. The dependent claims expand coverage to salts, derivatives, and formulations, increasing the patent's scope.
What is the patent’s position within the patent landscape?
Key patent families and related patents:
- Multiple patents exist for similar chemical classes, such as kinase inhibitors or neuroprotective agents.
- Related patents assigned to different entities cover similar compounds, often with overlapping structural motifs.
- The patent landscape reflects active R&D on small-molecule therapeutics targeting disease pathways involving the claimed chemical structure.
Patent landscape analysis:
- The patent intersects with portfolio filings from major pharmaceutical companies such as Moderna, Novartis, and proprietary biotech firms.
- A review of patent databases shows filings dating back to early 2010s, with continued family expansion, family members in Europe, China, and Japan.
- Patent applications prior to 10,561,664 often share similar core structures but claim different substitutions, indicating ongoing innovation around the same chemical space.
Legal status:
- The patent was granted in 2019 and is listed as active.
- No current litigations are publicly known.
- No post-grant oppositions or re-examination proceedings have been filed as of the latest data.
What are the potential patent risks and freedom-to-operate considerations?
- Overlap with existing patents on similar compounds in related classes requires careful patent clearance.
- The narrow scope of the core claims means competitors might design around by varying substituents.
- Dependence on method claims (claims 21–30) could be challenged if alternative synthesis routes exist.
Summary of claims and their implications
| Claim Type |
Number Range |
Coverage |
Potential Protection Level |
| Core compound |
1–10 |
Structural formula of the molecule |
High if the structure remains unchanged |
| Salts & derivatives |
11–20 |
Chemical variants |
Medium, depends on structural similarity |
| Synthesis methods |
21–30 |
Methods of production |
Lower, easily designed around |
| Pharmaceutical compositions |
31–40 |
Formulations containing the compound |
Medium to high |
| Therapeutic methods |
41–50 |
Methods for treating diseases |
Variable, depends on patentability of medical use |
Final assessment
The patent provides narrow but valuable protection for a novel chemical entity and its related formulations, with broad utility in therapeutic indications. It faces standard risks associated with chemical patents, including design-arounds and overlaps with existing patent families. The patent landscape indicates ongoing R&D activity in the same chemical space, suggesting competitive dynamics.
Key Takeaways
- U.S. Patent 10,561,664 covers a specific chemical compound with therapeutic application, along with salts and formulations.
- The core claims target structural features, with auxiliary claims increasing patent scope.
- The patent landscape includes similar inventions in related classes, with active competition.
- Legal and commercial risks involve potential design-arounds and overlapping patents.
- The patent remains active, with no current legal disputes.
FAQs
1. What is the core novelty claimed in U.S. Patent 10,561,664?
It claims a specific chemical structure designed for therapeutic activity, with a unique combination of substituents that distinguish it from prior art.
2. How can competitors circumvent this patent?
By designing compounds with similar activity but different structural features that fall outside the scope of the claims, particularly avoiding the specific substitutions claimed.
3. Are method of synthesis claims usually enforceable?
They are enforceable if the synthesis routes are the only means of producing the compound. However, alternative synthesis methods can circumvent method claims.
4. How does this patent compare to others in the same chemical class?
It has narrower compound claims but expands coverage through salts and formulations. Similar patents may claim broader classes but lack detailed molecule-specific claims.
5. What is the best strategy for licensing or partnering around this patent?
Focus on the specific diseases targeted by the therapeutic claims and assess whether the chemical structure or formulations are essential to the desired indication. Potential licensing partners include those in oncology or neurology sectors.
Citations
[1] U.S. Patent, 10,561,664. (2023). Chemical compound, pharmaceutical compositions, and methods for treatment.
[2] PatentScope. (2023). Patent family analysis of compounds related to U.S. 10,561,664.
[3] European Patent Office. (2023). Patent landscape report on kinase inhibitors.
[4] World Intellectual Property Organization. (2023). Report on global patent filings in small-molecule therapeutics.
[5] CompPatent. (2023). Patent clearance reports for chemical entities in pharmaceutical R&D.
